Trial · NCT03451591
Adverse events40
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 40
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| serious | Respiratory | Respiratory, thoracic and mediastinal disorders | Isosorbide Mononitrate XL (ISMN) | 1 | 181 | 1 |
| serious | Respiratory | Respiratory, thoracic and mediastinal disorders | Cilostazol | 2 | 182 | 2 |
| serious | Respiratory | Respiratory, thoracic and mediastinal disorders | ISMN XL and Cilostazol | 1 | 91 | 1 |
| serious | Respiratory | Respiratory, thoracic and mediastinal disorders | Neither ISMN Nor Cilostazol | 1 | 91 | 1 |
| serious | Gastrointestinal | Gastrointestinal disorders | Isosorbide Mononitrate XL (ISMN) | 7 | 181 | 7 |
| serious | Gastrointestinal | Gastrointestinal disorders | Cilostazol | 8 | 182 | 8 |
| serious | Gastrointestinal | Gastrointestinal disorders | ISMN XL and Cilostazol | 5 | 91 | 5 |
| serious | Gastrointestinal | Gastrointestinal disorders | Neither ISMN Nor Cilostazol | 1 | 91 | 1 |
| serious | Genitourinary | Renal and urinary disorders | Isosorbide Mononitrate XL (ISMN) | 1 | 181 | 1 |
| serious | Genitourinary | Renal and urinary disorders | Cilostazol | 4 | 182 | 4 |
| serious | Genitourinary | Renal and urinary disorders | ISMN XL and Cilostazol | 1 | 91 | 1 |
| serious | Genitourinary | Renal and urinary disorders | Neither ISMN Nor Cilostazol | 1 | 91 | 1 |
| serious | Haematological | Blood and lymphatic system disorders | Isosorbide Mononitrate XL (ISMN) | 1 | 181 | 1 |
| serious | Haematological | Blood and lymphatic system disorders | Cilostazol | 0 | 182 | 0 |
| serious | Haematological | Blood and lymphatic system disorders | ISMN XL and Cilostazol | 0 | 91 | 0 |
| serious | Haematological | Blood and lymphatic system disorders | Neither ISMN Nor Cilostazol | 1 | 91 | 1 |
| serious | Metabolic/Endocrine | Metabolism and nutrition disorders | Isosorbide Mononitrate XL (ISMN) | 0 | 181 | 0 |
| serious | Metabolic/Endocrine | Metabolism and nutrition disorders | Cilostazol | 0 | 182 | 0 |
| serious | Metabolic/Endocrine | Metabolism and nutrition disorders | ISMN XL and Cilostazol | 0 | 91 | 0 |
| serious | Metabolic/Endocrine | Metabolism and nutrition disorders | Neither ISMN Nor Cilostazol | 0 | 91 | 0 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03451591/events